Angiotensin II activates CaV1.2 Ca2+ channels through β‐arrestin2 and casein kinase 2 in mouse immature cardiomyocytes. (20th April 2017)

• Record Type: Journal Article
• Authors: Kashihara, Toshihide; Nakada, Tsutomu; Kojima, Katsuhiko; Takeshita, Toshikazu; Yamada, Mitsuhiko
• Is Part Of: Journal of physiology. Volume 595:Number 13(2017)
• Page Start: 4207
• Page End: 4225
• Publication Date: 2017-04-20
• Subjects: angiotensin II -- CaV1.2 Ca2+ channels -- cardiomyocytes; Physiology -- Periodicals; 612.005
• DOI: 10.1113/JP273883
• Languages: English
• ISSNs: 0022-3751

Abstract

Abstract : Key points: Angiotensin II (AngII) is crucial in cardiovascular regulation in perinatal mammalians. Here we show that AngII increases twitch Ca 2+ transients of mouse immature but not mature cardiomyocytes by robustly activating CaV 1.2 L‐type Ca 2+ channels through a novel signalling pathway involving angiotensin type 1 (AT1 ) receptors, β‐arrestin2 and casein kinase 2. A β‐arrestin‐biased AT1 receptor agonist, TRV027, was as effective as AngII in activating L‐type Ca 2+ channels. Our results help understand the molecular mechanism by which AngII regulates the perinatal circulation and also suggest that β‐arrestin‐biased AT1 receptor agonists may be valuable therapeutics for paediatric heart failure. Abstract: Angiotensin II (AngII), the main effector peptide of the renin–angiotensin system, plays important roles in cardiovascular regulation in the perinatal period. Despite the well‐known stimulatory effect of AngII on vascular contraction, little is known about regulation of contraction of the immature heart by AngII. Here we found that AngII significantly increased the peak amplitude of twitch Ca 2+ transients by robustly activating L‐type CaV 1.2 Ca 2+ (CaV 1.2) channels in mouse immature but not mature cardiomyocytes. This response to AngII was mediated by AT1 receptors and β‐arrestin2. A β‐arrestin‐biased AT1 receptor agonist was as effective as AngII in activating CaV 1.2 channels. Src‐family tyrosine kinases (SFKs) and casein kinase 2α'β (CK2α'β) were sequentially activated when AngII activated CaV 1.2 channels. A cyclin‐dependent kinase inhibitor, p27 Kip1 (p27), inhibited CK2α'β, and AngII removed this inhibitory effect through phosphorylating tyrosine 88 of p27 via SFKs in cardiomyocytes. In a human embryonic kidney cell line, tsA201 cells, overexpression of CK2α'β but not c‐Src directly activated recombinant CaV 1.2 channels composed of C‐terminally truncated α1C, the distal C‐terminus of α1C, β2C and α2 δ1 subunits, by phosphorylating threonine 1704 located at the interface between the proximal and the distal C‐terminus of CaV 1.2α1C subunits. Co‐immunoprecipitation revealed that CaV 1.2 channels, CK2α'β and p27 formed a macromolecular complex. Therefore, stimulation of AT1 receptors by AngII activates CaV 1.2 channels through β‐arrestin2 and CK2α'β, thereby probably exerting a positive inotropic effect in the immature heart. Our results also indicated that β‐arrestin‐biased AT1 receptor agonists may be used as valuable therapeutics for paediatric heart failure in the future. Key points: Angiotensin II (AngII) is crucial in cardiovascular regulation in perinatal mammalians. Here we show that AngII increases twitch Ca 2+ transients of mouse immature but not mature cardiomyocytes by robustly activating CaV 1.2 L‐type Ca 2+ channels through a novel signalling pathway involving angiotensin type 1 (AT1 ) receptors, β‐arrestin2 and casein kinase 2. A β‐arrestin‐biased AT1 receptor agonist, TRV027, was as effective as AngII in activating L‐type Ca 2+ channels. Our results help understand the molecular mechanism by which AngII regulates the perinatal circulation and also suggest that β‐arrestin‐biased AT1 receptor agonists may be valuable therapeutics for paediatric heart failure.